Exabis Library
Welcome to the e-CCO Library!
DOP50 The landscape of somatic mutations in non-neoplastic IBD-affected colon
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
DOP50: Effect of upadacitinib on extra-intestinal manifestations in patients with moderate to severe Crohn’s disease: data from the CELEST study
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
DOP50: Impact of Inflammatory Bowel Disease associated dysbiosis on bacterial quorum sensing mediated by Acyl-homoserine Lactone in human gut microbiota
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 2:22 PM
DOP50: Impact of Inflammatory Bowel Disease associated dysbiosis on bacterial quorum sensing mediated by Acyl-homoserine Lactone in human gut microbiota
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 10:43 AM
DOP50: Oral α4β7 integrin inhibitor MORF-057 demonstrates exposure driven biomarker response in non-human primates
2022
ECCO'22
Friday, 11 February 2022, 3:52 PM
DOP50: PINPOINT: The epidemiology of paediatric-onset Inflammatory Bowel Disease in the United Kingdom – a prospective, national, cohort study.
2024
ECCO'24 Stockholm
Tuesday, 30 April 2024, 5:03 PM
DOP50: Recommencement of Inflammatory Bowel Disease medications following colectomy for Ulcerative Colitis
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
DOP50: The landscape of somatic mutations in non-neoplastic IBD-affected colon
2020
ECCO'20 Vienna
Tuesday, 23 June 2020, 5:40 PM
DOP50: The landscape of somatic mutations in non-neoplastic IBD-affected colon
2020
ECCO'20 Vienna
Tuesday, 23 June 2020, 4:58 PM
1
DOP51 Investigation on the role of Par4-associated cell polarity and associated barrier defects in inflammatory bowel diseases
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
DOP51: Biomarker and pharmacokinetic data from the TURANDOT II open-label extension study of the anti-mucosal addressin cell adhesion molecule-1 (MAdCAM-1) antibody SHP647 in patients with ulcerative colitis
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
DOP51: Biomarker and pharmacokinetic data from the TURANDOT II open-label extension study of the anti-mucosal addressin cell adhesion molecule-1 (MAdCAM-1) antibody SHP647 in patients with ulcerative colitis
2019
ECCO'19 Copenhagen
Tuesday, 28 May 2019, 3:32 PM
1
DOP51: De-escalation of biological therapy in Inflammatory Bowel Disease patients following prior escalation
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
DOP51: Investigation on the role of Par4-associated cell polarity and associated barrier defects in Inflammatory Bowel Diseases
2020
ECCO'20 Vienna
Tuesday, 23 June 2020, 5:40 PM
DOP51: Investigation on the role of Par4-associated cell polarity and associated barrier defects in Inflammatory Bowel Diseases
2020
ECCO'20 Vienna
Tuesday, 23 June 2020, 4:58 PM
1
DOP51: Loss of PTPN23 in the intestinal epithelium results in epithelial hyperproliferation and lethal diarrhea in a microbiota dependent manner
2022
ECCO'22
Friday, 11 February 2022, 3:52 PM
DOP51: Mucosa-associated microbial signatures associate with objective response prior to the start of anti-TNFα but not vedolizumab or ustekinumab in Crohn's disease patients
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 10:43 AM
DOP51: Mucosa-associated microbial signatures associate with objective response prior to the start of anti-TNFα but not vedolizumab or ustekinumab in Crohn’s disease patients
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 2:22 PM
DOP51: Risk of kidney failure in patients with Inflammatory Bowel Disease undergoing colectomy: a nationwide cohort study
2024
ECCO'24 Stockholm
Tuesday, 30 April 2024, 5:03 PM
DOP52 The phenotype of NOD-scid IL-2Rγnull mice reconstituted with peripheral blood mononuclear cells from patients with Crohn’s disease or ulcerative colitis reflects the respective disease
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM